Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immunopathology and Immunotherapy of Hodgkin Lymphoma Publisher



Ebadi M1 ; Keshavarzfathi M2, 3 ; Zeng Y4 ; Gkotzamanidou M5 ; Rezaei N6, 7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Division of Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States
  2. 2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, AZ, United States
  5. 5. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
  6. 6. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors Published:2020


Abstract

Immunotherapy has led to promising results in the treatment of malignancies in recent decades. In view of the suboptimal results obtained by applying other treatment modalities in the treatment of Hodgkin lymphoma (HL), attention has been drawn to immunotherapy as an efficient alternative or complement therapy. This chapter seeks to discuss a wide spectrum of immunotherapeutic approaches, from initial monoclonal antibodies to novel techniques developed in recent years, which are still at their infancy. Since correct understanding of the underlying immunopathology seems inevitable in efficient immunotherapy and development of future techniques, a brief description with the emphasis on suitable targets for immunotherapy is given before discussing various immunotherapies. © Springer Nature Switzerland AG 2020. All rights reserved.
Related Docs
View other Related Docs
1. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
2. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
3. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
4. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
5. Efficacy of Nivolumab As Checkpoint Inhibitor Drug on Survival Rate of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: A Meta-Analysis of Prospective Clinical Study, Clinical and Translational Oncology (2019)
6. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
7. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
8. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (22)
Hamid Reza Mirzaei (3)
Other Related Docs
9. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
10. Tumor Immunology, Clinical Immunology (2022)
11. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma, Expert Review of Anticancer Therapy (2021)
12. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
13. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
14. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
15. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)
16. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
17. Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma, International Reviews of Immunology (2019)
18. Recent Progress in Topical and Transdermal Approaches for Melanoma Treatment, Drug Delivery and Translational Research (2025)
19. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
20. Liothyronine Could Block the Programmed Death-Ligand 1 (Pdl1) Activity: An E-Pharmacophore Modeling and Virtual Screening Study, Journal of Receptors and Signal Transduction (2022)
21. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
22. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
23. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
24. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)
25. Licensed Monoclonal Antibodies and Associated Challenges, Human Antibodies (2015)
26. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
27. Adcs, As Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies, Current Drug Delivery (2020)
28. Targeting Regulatory T Cells by Curcumin: A Potential for Cancer Immunotherapy, Pharmacological Research (2019)
29. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
30. Immune Checkpoints and Graves’ Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review, Journal of Ophthalmic and Vision Research (2024)
31. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
32. A Comprehensive Review About the Utilization of Immune Checkpoint Inhibitors and Combination Therapy in Hepatocellular Carcinoma: An Updated Review, Cancer Cell International (2022)
33. Immune Checkpoint Inhibitors and Cardiotoxicity: Possible Mechanisms, Manifestations, Diagnosis and Management, Expert Review of Anticancer Therapy (2021)
34. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
35. The Role of T Helper 17 and Regulatory T Cells in Tumor Microenvironment, Immunopharmacology and Immunotoxicology (2019)
36. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
37. Car-Nk Cells: A Promising Cellular Immunotherapy in Lymphoma, Expert Opinion on Biological Therapy (2023)
38. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)
39. Natural Killer Cell–Based Immunotherapy: From Transplantation Toward Targeting Cancer Stem Cells, Journal of Cellular Physiology (2018)
40. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
41. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
42. Expression of Pd1 and Pdl1 As Immune-Checkpoint Inhibitors in Mantle Cell Lymphoma, BMC Cancer (2022)
43. Immune Checkpoint Inhibitors Therapy As the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape, Critical Reviews in Oncology/Hematology (2024)
44. Is Gata3 Useful for Differentiating Between Classical Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma? a Two-Center Study in Tehran, Iran During 2016 to 2022, Asian Pacific Journal of Cancer Prevention (2025)
45. Pd-1/Pd-L and Autoimmunity: A Growing Relationship, Cellular Immunology (2016)
46. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)
47. Cancer Imaging With Radiolabeled Monoclonal Antibodies, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)
48. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
49. New Approaches in Cancer Immunotherapy: Review Article, Tehran University Medical Journal (2018)
50. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)